Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vectus Biosystems Limited ( (AU:VBS) ) has issued an announcement.
Vectus Biosystems Limited has signed a binding agreement with XORTX Therapeutics Inc. for the sale of its VB4-P5 Renal Small Molecule Compound, a move that aligns with its strategy to develop and validate drug candidates for commercial partnerships. The company is also actively pursuing licensing opportunities, particularly in China, and is focused on reducing operational costs while exploring collaborations to fund further clinical studies, reflecting its commitment to advancing its anti-fibrotic therapies.
More about Vectus Biosystems Limited
Vectus Biosystems Limited is a biotechnology company focused on developing treatments for fibrosis, targeting major diseases such as heart, kidney, and liver conditions. Since its listing on the ASX in 2016, the company has concentrated on its lead compound, VB0004, which aims to treat tissue hardening and high blood pressure. Vectus has conducted successful pre-clinical trials and progressed VB0004 through significant milestones, including human trials and pharmaceutical scale-up, aligning with its strategy to make its drug candidates commercially attractive to pharmaceutical partners.
Average Trading Volume: 55,753
Technical Sentiment Signal: Buy
Current Market Cap: A$6.93M
For a thorough assessment of VBS stock, go to TipRanks’ Stock Analysis page.